Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation

N Jaffe; S R Patel; R S Benjamin

Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation

Hematol Oncol Clin North Am. 1995 Aug;9(4):825-40.

Authors

N Jaffe¹, S R Patel, R S Benjamin

Affiliation

¹ University of Texas Medical School at Houston, USA.

PMID: 7490244

Abstract

Chemotherapy in osteosarcoma has had a major impact in attaining metastasis-free survival, and the cure rates with the use of modern regimens range from 65% to 75%. Preoperative chemotherapy has facilitated surgical resection of the primary tumor, rendering increased numbers of candidates for limb salvage. The effects on the primary tumor may be used as a predictive factor in determining outcome.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Neoplasms / drug therapy*
Bone Neoplasms / therapy
Chemotherapy, Adjuvant
Cisplatin / administration & dosage
Cisplatin / therapeutic use
Clinical Trials as Topic
Disease-Free Survival
Doxorubicin / administration & dosage
Humans
Infusions, Intra-Arterial
Methotrexate / administration & dosage
Multicenter Studies as Topic
Osteosarcoma / drug therapy*
Osteosarcoma / therapy
Randomized Controlled Trials as Topic
Remission Induction
Survival Rate
Treatment Outcome

Substances

Doxorubicin
Cisplatin
Methotrexate